Background Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumours associated with tuberous sclerosis complex. We assessed the effi cacy and safety of two trough exposure concentrations of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous sclerosis complex.
Introduction
Epilepsy is the most common neurological symptom of tuberous sclerosis complex, an autosomal dominant genetic disorder, and is reported in up to 85% of patients with the condition.
1,2 Nearly two-thirds of patients with tuberous sclerosis complex present with seizures in the fi rst year of life, often as focal seizures or infantile spasms. 1, 2 Early onset of epilepsy and particularly untreated early-onset epilepsy is associated with an increased risk of neurodevelopmental disabilities, including autism spectrum disorder and intellectual disability. 2 Seizures associated with tuberous sclerosis complex can be focal, multifocal, or generalised, and are typically diffi cult to control. 3 More than 60% of patients are resistant to standard therapies such as antiepileptic drugs, epilepsy surgery, ketogenic diet, and vagal nerve stimulation, 1,2 as opposed to only 30-40% of patients with epilepsy without tuberous sclerosis complex. 4 To date, tuberous sclerosis complex is treated symptomatically with antiepileptic drugs that are not specifi c for the underlying cause. Targeting of diseasespecifi c molecular signalling mechanisms that drive the development of seizures has been previously suggested in tuberous sclerosis complex or other epilepsy aetiologies, 5 but not implemented. Antiepileptic drugs render neurons less excitable, typically by interacting with transmembrane ion channels. They can be particularly eff ective for some specifi c seizure types or epilepsy syndromes (eg, carbamazepine for localisation related epilepsy, vigabatrin for infantile spasms, and clonazepam for Angelman's syndrome). However, antiepileptic drugs are not necessarily developed for or directed against a specifi c molecular pathomechanism. 5 Aberrant mammalian target of rapamycin (mTOR) signalling results in hamartomas, and neuropsychiatric disorders and epilepsy associated with tuberous sclerosis complex. 2, 3 Overactivation of mTOR leads to giant, dysplastic neurons, abnormal axonogenesis and dendrite formation, increased excitatory synaptic currents, reduced myelination, and disruption of the cortical laminar structure. [6] [7] [8] [9] [10] [11] Dysregulated mTOR activity due to mutations in upstream pathway genes, including STRADα, DEPDC5, and PI3K, has also been implicated in epileptogenesis and seizures associated with cortical malformations. 12 At present, tuberous sclerosis complex is the best-characterised disease associated with mTOR pathway overactivation. Findings from preclinical studies 8, 11 have shown that treatment with mTOR inhibitors could increase survival, prevent the development of new-onset seizures, and ameliorate existing epilepsy. Case reports and open-label studies suggest benefi cial eff ects of everolimus in patients with epilepsy associated with tuberous sclerosis complex. [13] [14] [15] [16] [17] Everolimus is an mTOR inhibitor that has been approved for the treatment of subependymal giant-cell astrocytoma and renal angiomyolipoma in patients with tuberous sclerosis complex. 14, 18 Another mTOR inhibitor, sirolimus, has been approved for the treatment of lymphangioleiomyomatosis in tuberous sclerosis complex.
We postulated that everolimus might improve seizures by targeting the specifi c molecular defect in patients with tuberous sclerosis complex and treatment-resistant focal epilepsy. Examining Everolimus in a Study of Tuberous Sclerosis Complex (EXIST-3) evaluated the effi cacy and safety of two dosing regimens of adjunctive everolimus 
Research in context
Evidence before this study Limited evidence is available on the optimal treatment of epilepsy in patients with tuberous sclerosis complex. We searched PubMed for English-language studies using the terms "tuberous sclerosis complex" or "tsc" and "epilepsy" or "seizure", published up to June 23, 2016 
Added value of this study
This phase 3 multicentre study provides the benefi ts and risks of adding everolimus as adjunctive therapy to between one and three antiepileptic drugs in patients with tuberous sclerosis complex who have shown a high burden of treatment-resistant seizures (at least 16 in an 8-week period before randomisation). Additionally, this study provides the fi rst estimates of the optimal range of everolimus exposure suitable in patients with tuberous sclerosis complex and seizures.
Implications of all the available evidence By comparison with previous studies, which were either case series, retrospective cohort studies, prospective studies of small sample size, or prospective clinical trials with seizure outcome assessed as secondary measure, the fi ndings from EXIST-3 provide evidence that everolimus might be an eff ective treatment option as adjuvant therapy for children and adults with treatment-resistant epilepsy. EXIST-3 extends the use of everolimus for seizures in tuberous sclerosis complex, in addition to the benefi t observed for other aspects of the disease (subependymal giant-cell astrocytoma, renal angiomyolipoma, and facial angiofi broma). The time to effi cacy observed in the study suggests that everolimus, unlike conventional antiepileptic drugs, provides a unique mechanism of action through targeting of mTOR overactivation. This study's fi ndings also demonstrate the short-term benefi t of everolimus when added to best available antiepileptic drug therapy.
compared with placebo in patients with tuberous sclerosis complex and treatment-resistant focal epilepsy.
Methods

Study design and participants
EXIST-3 is a three-arm, prospective, randomised, multicentre, double-blind, placebo-controlled, phase 3 study. It includes an initial 8-week baseline phase, followed by an 18-week core phase (reported here) and a 48-week extension phase (which will be reported on completion). Patients aged 2-65 years with a confi rmed diagnosis of tuberous sclerosis complex and treatmentresistant epilepsy, with 16 or more seizures during the 8-week baseline phase (with no continuous 21-day seizure-free period) and receiving between one and three antiepileptic drugs at a stable dose for at least 12 weeks before randomisation were included. Patients were excluded if they had subependymal giant-cell astrocytomas requiring immediate surgical intervention, seizures secondary to drug abuse, psychogenic nonepileptic seizures, active infantile spasms, or an episode of status epilepticus within 1 year before study inclusion. During the baseline phase, patients or their caregivers completed a seizure diary, recording seizure types and frequencies. In this population, many of whom have developmental delay, there are many seizure mimickers, including inattentive episodes, tics, and stereotyped behavioural events (known as stereotypies). 19 To ensure reliable and consistent classifi cation of seizures across patients, seizures reported by patients and caregivers were entered into a seizure identifi cation form, separated into probable seizures (>80% likelihood of being an epileptic seizure) and questionable seizures (50-80% likelihood) by the investigators. Only probable seizures were counted towards the primary outcome. Focal seizures with retained awareness (simple partial seizures) were considered questionable if they had no motor or observable component, unless they had electroencephalogram (EEG) confi rmation. Stares without automatisms or other clear seizure-like manifestations were also counted as questionable. Independent reviewers (epileptologists from the Epilepsy Study Consortium, responsible for harmonising seizure classifi cations in the study) confi rmed the seizure classifi cation and designation as probable or questionable. Because multiple seizure types are present in tuberous sclerosis complex (a disease of focal pathology), all seizures were considered to be focal in onset unless an EEG confi rmed a generalised onset. Seizures were assigned to one of six categories: focal motor with retained awareness; focal non-motor with impaired awareness (including atypical absence or bland focal with altered awareness); focal motor with impaired awareness; other focal motor seizures (including those often classifi ed as of generalised origin-ie, focal to bilateral myoclonic, clonic, tonic, atonic); focal to bilateral tonic-clonic; and EEG-confi rmed generalised onset seizures (not included in seizure count for primary analysis but included in an exploratory analysis).
All patients (or their legal representatives) provided written informed consent before entering the baseline phase. The study was done in accordance with the principles of Good Clinical Practice, the Declaration of Helsinki, and all local regulations. The study protocol (appendix) and all amendments were reviewed and approved by independent ethics committees or institutional review boards for each centre.
Randomisation and masking
At the end of the baseline phase, eligible patients entered the core phase and were randomly assigned (1:1:1), via permuted-block randomisation (block size of six) implemented by Interactive Response Technology (IRT) software, to receive placebo, everolimus titrated to a target trough concentration (C min ) of 3-7 ng/mL (lowexposure everolimus), or everlimus titrated to a target C min of 9-15 ng/mL (high-exposure everolimus), in addition to a stable regimen of one to three antiepileptic drugs. Randomisation was stratifi ed by age subgroup (<6 years, 6 to <12 years, 12 to <18 years, and ≥18 years). Dose adjustments to attain the target C min were done during the fi rst 6 weeks of the core phase, and as needed during the subsequent 12-week maintenance period.
Patients, investigators, site personnel, and the sponsor's study team were masked to treatment allocation, but allocation was not concealed from personnel in charge of drug supply, implementation of the randomisation list, and pharmacokinetic bioanalysis. The Data Safety Monitoring Board (DSMB) independent statistician and programmer were semi-blind to treatment allocation at the time of DSMB meetings. Study medication consisted of everolimus 2 mg pills and identical placebo pills, with both medication types being dispensed in yellow or blue blister packs. To maintain blinding, any patient in any treatment group could receive either or both colours of pills, and there were random dummy-dose titrations of placebo tablets in both the placebo group and the low-exposure group.
Procedures
We determined the starting dose of everolimus on the basis of patients' age, body-surface area, and concomitant use of cytochrome P450 3A4 (CYP3A4)/P-glycoprotein (PgP) inducers. For patients younger than 10 years, the starting dose of everolimus was 6 mg/m² per day for those not receiving CYP3A4/PgP inducers and 9 mg/m² per day for those receiving CYP3A4/PgP inducers; for patients aged 10-18 years, the equivalent doses were 5 mg/m² per day and 8 mg/m² per day, and for those older than 18 years were 3 mg/m² per day and 5 mg/m² per day, respectively. During the fi rst 6 weeks of the core phase, up to three dose adjustments were allowed to reach the targeted everolimus trough range. Further dose adjustments were possible as needed during the 12-week maintenance period of the core phase. Dose adjustments were 2 mg for patients not receiving concomitant CYP3A4 inducers and 4 mg for patients receiving CYP3A4 inducers. Dose increases and decreases were performed for patients with C min values lower and higher than the target range, respectively.
Study treatment continued until the end of the core phase unless there was loss of seizure control, an episode of status epilepticus, interruption of one or more concomitant antiepileptic drugs for more than 7 days, intolerable toxic eff ects, or withdrawal of consent. Patients or their caregivers continued to record occurrence or absence of seizures on each day throughout the core phase. Patients were then off ered to continue in the extension phase, in which all patients received everolimus titrated to achieve a C min of 6-10 ng/mL (automated, IRT controlled) followed by non-automated, investigator-prescribed titrations to achieve a C min of 3-15 ng/mL.
The Vineland II Adaptative Behavior Scale was completed at baseline, at completion of the core phase, then every 6 months thereafter. This scale was completed by the physician while interviewing and observing the patient (survey interview form), but could be completed by the parent or their caregiver if the patient was unable to provide the information required (parent or caregiver form).
Outcomes
The primary effi cacy endpoint was change from baseline in seizure frequency for each of the two everolimus C min ranges compared with placebo during the 12-week maintenance period of the core phase, expressed as response rate (reduction in seizure frequency) and median percentage reduction in seizure frequency. Seizure frequency corresponds to the ratio between the number of seizures and the number of days on which seizure information was known within the same period of time (baseline or maintenance phase).
The secondary endpoints included frequency of seizure-free days during the maintenance period, seizure-free rate (patients remaining seizure free during the entire maintenance period), the proportion of patients achieving at least a 25% reduction in seizure frequency from baseline, and exposure-response relationship analysis. A sensitivity analysis was done to assess the robustness of the primary and secondary effi cacy endpoints by considering the assessment period as the entire core phase (we used the 12-week maintenance period in the primary analysis to comply with a European Medicines Agency guideline on clinical investigation of medicinal products in the treatment of epileptic disorders). 20 The study also assessed safety during the core phase. We assessed adverse events according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.03. 21 
Statistical analysis
EXIST-3 was planned as a phase 3 registration study in the absence of previous dose-fi nding studies in this indication of epilepsy associated with tuberous sclerosis complex. A literature review revealed that several recent studies of focal seizures and Lennox-Gastaut syndrome were powered to achieve seizure reductions of 16-22% greater than placebo. In these studies, median reduction in seizure frequency in placebo groups ranged from 11% to 18%. [22] [23] [24] [25] In light of these studies, we chose a planned sample size of 345 patients (115 per group), to provide 90% power to detect a diff erence in response rate from 15% on placebo to 35% in each of the two everolimus groups, with each test at the 1·25% one-sided signfi cance level. At least 90% power was also expected for percentage reduction in seizure frequency, because response rate is less sensitive due to loss of information in dichotomising a continuous variable. Owing to a failure of the IRT system to titrate the everolimus dose during the fi rst 5 months of the study, there was a concern about potential loss of power, particularly for the high-exposure everolimus group where most patients were expected to need at least one dose increase to reach the targeted trough range of 9-15 ng/mL. Without unblinding, we determined that a maximum of 18 patients in the highexposure everolimus might have missed dose titrations. Therefore, to mitigate against a potential loss of power, we increased the planned sample size in the highexposure everolimus group (in a blinded manner) by ten patients.
Descriptive statistics were used to summarise the baseline characteristics of the study population. The full analysis set was the primary effi cacy population, comprising all randomly assigned patients. We compared response rate between each everolimus group versus the placebo group using Cochran-MantelHaenszel χ² tests stratifi ed by age subgroup. For percentage reduction in seizure frequency, we used a rank ANCOVA model, with baseline seizure frequency as a covariate, and stratifi ed by age subgroup. For each of the two primary variables (response rate and percentage reduction in seizure frequency), a Bonferroni-Holm procedure was used to ensure overall family-wise type I error rates of 2·5% (one sided), taking into account the comparison of each everolimus group with placebo; no multiplicity adjustment was made to take account of the two primary variables. The relationship between effi cacy parameters and exposure to study drug was assessed using regression models (with logit function for response rate and linear function for seizure frequency). Safety analysis was done with the safety set of all patients who received at least one dose of study drug and had at least one post-baseline safety assessment.
We did statistical analyses with SAS (version 9.2). This trial is registered with ClinicalTrials.gov, number NCT01713946.
Role of the funding source
The study was designed by academic investigators and representatives of the funder, Novartis Pharmaceuticals Corporation. Data were collected electronically using data management systems of a contract research organisation designated by the funder and were analysed by the funder's statistical team. All authors had full access to the data for interpretation and analysis, were involved in development and approval of the report, and had the fi nal responsibility for the decision to submit for publication. All authors vouch for the accuracy and completeness of the reported data, and attest that the study conformed to the protocol and statistical analysis plan.
Results
Between July 3, 2013, and May 29, 2015, 366 patients (190 men, 176 women) were enrolled from 99 centres in 25 countries worldwide and randomly assigned to receive placebo (n=119), low-exposure everolimus (n=117), or high-exposure everolimus (n=130; fi gure 1). The median age was 10·1 years (range 2·2-56·3) with 104 patients (28%) younger than 6 years and 67 (18%) patients aged 18 years or older (table 1) . Of all patients enrolled, 178 (49%) had previously tried and not responded to six or more previous antiepileptic drugs. Antiepileptic drugs that failed most frequently before screening were levetiracetam in 245 (67%) patients, vigabatrin in 243 (66%) patients, and topiramate in 214 (58%) patients. At baseline, focal motor seizures with retained awareness were present in 71 patients (19%), focal non-motor seizures with impaired awareness in 165 (45%), focal motor seizures with impaired awareness in 95 (26%), other focal motor seizures in 149 (41%), focal to bilateral tonic-clonic seizures in 68 (19%), and EEG-confi rmed generalised onset seizures in six (2%; table 2). The median seizure frequency per 28 days at baseline excluding EEG-confi rmed generalised onset seizures was 42·0 (range 5·3-926·7) in the placebo group, 34·5 (5·5-771·5) in the low-exposure group, and 37·8 (1·0-873·5) in the high-exposure group.
346 (95%) patients completed the core phase. Five (4%) patients in the placebo group, seven (6%) in the lowexposure group, and eight (6%) in the high-exposure everolimus group discontinued treatment during the core phase. The most common reason for treatment discontinuation was adverse events in all treatment groups ( high-exposure group was 7·5 mg/m² per day (1·4-24·4). The median C min observed at the end of the core phase for patients randomly assigned to the low-exposure group was 5·1 ng/mL (1·4-25·3) and in the high-exposure everolimus group was 8·3 ng/mL (0·8-22·0). The median seizure frequency per week at baseline was 10·5 (range 1·3-231·7) in the placebo group, 8·6 (1·4-192·9) in the low-exposure group, and 9·5 (0·3-218·4) in the high-exposure group, and at the end of core phase was 8·5 (0-217·7), 6·8 (0-193·5), and 4·9 (0-133·7), respectively. In the placebo group, 18 of 119 patients had a 50% or greater reduction in seizure frequency during the maintenance period compared with baseline, equivalent to a response rate of 15·1% (95% CI 9·2-22·8); the median percentage reduction in seizure frequency was 14·9% (95% CI 0·1-21·7). By comparison, everolimus was associated with a signifi cantly greater response rate (33 of 117 patients in the low-exposure group, response rate 28·2% [95% CI 20·3-37·3], p=0·0077; and 52 of 130 patients in the high-exposure group, response rate 40·0%
[31·5-49·0], p<0·0001) and a signifi cantly greater median percentage reduction in seizure frequency (in the lowexposure group, 29·3% [95% CI 18·8-41·9], p=0·0028; and in the high-exposure group, 39·6% [35·0-48·7], p<0·0001; fi gure 2). The odds of achieving a 50% or greater reduction in seizure frequency was 2·2-times higher (95% CI 1·2-4·2) for low-exposure everolimus than placebo and 3·9-times higher (2·1-7·3) for highexposure everolimus than for placebo. Results of the sensitivity analysis (using the full core phase instead of the 12-week maintenance period) were consistent with the primary analysis; 13 patients had a 50% or greater reduction in seizure frequency (response rate 10·9% [95% CI 5·9-18·0]) for placebo compared with 29 patients (24·8% [17·3-33·6]) for low-exposure everolimus and 42 patients (32·3% [24·4-41·1]) for high-exposure everolimus, and the median percentage reduction in seizure frequency was 10·7% (95% CI -1·6 to 17·6) for placebo compared with 18·4% (11·7-29·5) for lowexposure everolimus and 34·9% (28·5-41·1) for highexposure everolimus.
A 25% or greater reduction in seizure frequency was observed in 45 patients (37·8% [95% CI 29·1-47·2]) in the placebo group, 61 patients (52·1% [42·7-61·5]) in the lowexposure everolimus group, and 91 patients (70·0% [61·3-77·7]) in the high-exposure everolimus group (fi gure 2). The seizure-free rate was 0·8% (95% CI 0-4·6; one patient) for the placebo group, 5·1% (1·9-10·8; six patients) for the low-exposure everolimus group, and 3·8% (1·3-8·7; fi ve patients) for the high-exposure everolimus group. The median number of seizure-free days (per 28-day period) increased from baseline by 2·0 in the low-exposure group and 4·0 days in the high-exposure group, compared with 0·5 days in the placebo group. We noted seizure reduction with everolimus treatment among multiple seizure types (fi gure 2), and the seizure reduction fi ndings were essentially unchanged when generalised onset seizures confi rmed by EEG (reported in six patients) were included in the analysis (data not shown).
Logistic and linear regression models stratifi ed by age subgroup and adjusted by baseline seizure frequency supported exposure (expressed as time-normalised [TN] C min , denoting an estimated average of C min over the maintenance period) as a strong predictor of response rate and seizure frequency in the maintenance period of the core phase; a doubling of TN C min was associated with a statistically signifi cant 2·2-times increase (95% CI 1·3-3·5; p=0·0017) in the odds for a response and a statistically signifi cant 28·3% reduction (95% CI 11·7-41·8; p=0·0019) in seizure frequency.
In the placebo group, the median percentage reduction in seizure frequency peaked at week 10, and remained relatively stable throughout the rest of the core phase (fi gure 2). However, everolimus-treated patients reported an increasing benefi t until the end of the core phase (week 18). A similar pattern of diff erentiation between patients in the placebo group and those in the everolimus groups was observed when the measure of effi cacy was seizure freedom (fi gure 2). Quantifying these observations, a repeated measures analysis including both exposure and fi xed time intervals of 2 weeks as predictors noted that a doubling of TN C min was associated with a signifi cant average reduction of 9·7% (95% CI 5·7-13·6; p<0·0001) in seizure frequency across the core phase. The time under treatment was also associated with a statistically signifi cant 4·8% reduction (95% CI 3·2-6·3; p<0·0001) in seizure frequency for each period of 15 days more under treatment. All patients assigned to placebo, low-exposure everolimus, or high-exposure everolimus received at least one dose of study drug and had at least one post-baseline assessment, and were therefore included in the safety anaylsis. The most common all-grade adverse events of any cause reported in more than 15% of patients in either treatment group during the core phase in the everolimus groups included stomatitis, diarrhoea, nasopharyngitis, pyrexia, and upper respiratory tract infection (table 3) . Overall, 13 patients (11%) in the placebo group, 21 (18%) in the low-exposure everolimus group, and 31 (24%) in the high-exposure everolimus group experienced grade 3 or 4 adverse events. Stomatitis of grade 3 or 4 severity was reported in four patients (3%) in the low-exposure group and fi ve patients (4%) in the high-exposure group. The other most frequent grade 3 or 4 adverse events (occurring in more than two patients) reported with everolimus included neutropenia (two [2%] patients in the lowexposure group and three [2%] patients in the highexposure group), pneumonia (one [1%] patient and three [2%] patients, respectively), and irregular menstruation (three [2%] patients in the high-exposure group only). Serious adverse events were reported in three (3%) patients in the placebo group, 16 (14%) patients in the lowexposure group, and 18 (14%) patients in the highexposure group. Adverse events leading to discontinuations were reported in two (2%) patients receiving placebo, six (5%) patients receiving low-exposure everolimus, and four (3%) patients receiving high-exposure everolimus, with stomatitis being the most common reason (two [2%] patients in the low-exposure group and two [2%] patients in the high-exposure group). Adverse events leading to a dose reduction or temporary interruption were reported in nine (8%), 28 (24%), and 46 (35%) patients in the placebo, low-exposure everolimus, and high-exposure everolimus groups, respectively. No deaths were reported during the core phase. Pharmacokinetic modelling assessing the exposure-safety relationship of everolimus showed that the changes in rates of stomatitis and infections observed upon doubling of exposure were not statistically signifi cant (data not shown).
Discussion
In this prospective, randomised phase 3 trial, everolimus produced a signifi cant reduction in seizure frequency in patients with treatment-resistant epilepsy and tuberous sclerosis complex compared with placebo. At baseline, nearly half of patients had failed treatment with six or more previous antiepileptic drugs, and the median seizure frequency was 37·5 per 28 days, suggesting a heavily pretreated population with a severe seizure burden. Tuberous sclerosis complex is associated with various seizure types and epilepsy syndromes. 1 Previous studies of antiepileptic drugs have focused on either a specifi c syndrome (eg, Lennox-Gastaut syndrome) or a single seizure type (eg, primary generalised tonic-clonic seizure, atonic seizure). 26, 27 EXIST-3 is, to our knowledge, the largest cause-specifi c epilepsy drug trial done so far; we enrolled patients with a known seizure cause, irrespective of ictal semiology or epilepsy syndrome, from 99 centres across 25 countries. Because everolimus targets the molecular basis of the underlying disease in patients with tuberous sclerosis complex, it could produce a clinically signifi cant reduction in seizure frequency. Everolimus might also have activity in epilepsies associated with mTOR activation from other causes, such as DEPDC5 or STRAD mutations. 5 Few clinical trials have assessed the role of mTOR inhibitors for seizures associated with tuberous sclerosis complex. 15, 28 Our study showed an improvement in seizure control with everolimus among multiple seizure types, suggesting that everolimus can treat a variety of seizure types in this population irrespective of epilepsy syndrome. The odds for response in patients treated with everolimus were 2·2-times (low-exposure group) and 3·9-times (high-exposure group) higher than with placebo. A previous uncontrolled study with everolimus showed a 50% or greater reduction in seizures in 12 (60%) of 20 patients, with an overall median decrease in seizure frequency of 73% (p<0·001) and a median 70% decrease in cumulative seizure duration (p=0·020). 15 Results from the sensitivity analysis (adjusted for an 18-week follow-up period) in the EXIST-3 study were consistent with the primary analysis.
During the core phase, the safety profi les of the low-exposure everolimus and high-exposure everolimus groups were similar to each other. The decision to use the National Cancer Institute Common Toxicity Criteria for Adverse Events assessment scale to evaluate the safety profi le of the study treatment was in accordance with our experience from previous studies of everolimus in tuberous sclerosis complex for the treatment of subependymal giant-cell astrocytoma and renal angiomyolipoma. In most epilepsy studies, adverse events are usually classifi ed only into "mild", "moderate", and "severe". The number of severe adverse events and events leading to discontinuation in this study were consistent with fi ndings from previous studies of antiepileptic drugs. For example, in a study of perampanel, 26 six (7·4%) of 81 patients experienced serious adverse events, and nine (11·1%) had adverse events leading to discontinuation; by comparison, we noted a somewhat higher frequency of severe adverse events (21%) with everolimus in this study, but a substantially lower frequency of adverse events leading to discontinuation (4%). The frequency and incidence of adverse events with everolimus reported here were consistent with the known safety profi le of everolimus in tuberous sclerosis complex. 14, 18, 29 No new safety signals were identifi ed. Importantly, the common side-eff ects of everolimus were generally non-overlapping with the typical side-eff ects of antiepileptic drugs such as sleepiness, dizziness, and fatigue, which might make it easier for patients to tolerate the medication in combination with other antiepileptic drugs, and could account for the relatively low dropout rate in the study.
Previously, everolimus was reported to reduce the volume of subependymal giant-cell astrocytoma 29 and renal angiomyolipoma, 18 which led to the approval of everolimus in these indications. Everolimus has also been reported to improve the appearence of skin lesions (facial angiofi broma) in these patients. 14 Yet results from the current study demonstrate the clinical benefi ts of everolimus for another manifestation of tuberous sclerosis complex, treatment-resistant seizures. Everolimus diff ers from other antiepileptic drugs by targeting the dysregulation of the mTOR cellular signalling pathway, providing an opportunity for therapeutic synergy. Everolimus initiated for one of its approved indications could also reduce seizures, and everolimus initiated for seizures could be expected to improve other manifestations of the disorder (eg, subependymal giant-cell astrocytoma, renal angiomyolipoma, facial angiofi broma). However, it should be noted that the exposure-response relationship diff ers among the diff erent indications.
Linear mixed models supported a statistically and clinically signifi cant association between a two-times increase in TN C min and a 28·3% reduction in seizure frequency. In the studies of subependymal giant-cell astrocytoma and angiomyolipoma, a two-times C min increase was associated with a non-clinically signifi cant 10% (unpublished) and 13% statistically signifi cant reduction in volumes, 30 respectively. This diff erence in exposure-response relationship might relate to higher interindividual variability of exposure and a threshold eff ect in the tumour-volume-based trials, or greater sensitivity of synaptic plasticity and neuronal hyperexcitability in this seizure study.
Several limitations in our study should be noted. Firstly, the results showed short-term benefi t of everolimus when added to best-available antiepileptic drug therapy during the core phase. With a potential need for multiyear or lifelong therapy in patients with tuberous sclerosis complex, exploration of longer-term durability of effi cacy and maintenance of safety and tolerability of everolimus is essential. With nearly 90% of patients continuing treatment in the extension phase, the EXIST-3 study could, in time, provide additional long-term effi cacy and safety data relating to everolimus in patients with treatmentresistant seizures associated with tuberous sclerosis complex. Active surveillance and proactive management of adverse events are warranted in these patients, as in a phase 1/2 study where everolimus maintained seizure control for 4 years in 14 of 18 patients and had a tolerable safety profi le. 31 Second, in this study we had intended to report the eff ect of everolimus on patient behaviour using the Vineland Adaptive Behavior Scale Survey; however, the substantial intellectual disability in the study population resulted in frequent failure of investigators to perform the survey at baseline and yielded profound fl ooring (ie, scores below which the test can no longer distinguish levels of behavioural attainment) in many surveys, limiting the interpretation of results. Finally, we noted less diff erentiation in exposure than anticipated between the two everolimus groups, because of lower-than-expected exposure in the high-exposure everolimus group (median C min values at the end of the core phase were 5·1 ng/mL for the low-exposure everolimus group and 8·3 ng/mL for the high-exposure everolimus group). This lack of diff erentiation seems to have occurred because, in some patients, three titration steps of everolimus 2 mg or 4 mg might not have been suffi cient to achieve the targeted trough range of 9-15 ng/mL (eg, patients with high everolimus clearance or high body-surface area). Despite overlap in actual C min values among the everolimus treatment groups, the range of exposures acheived in the study population was adequately broad to permit a robust determination of the everolimus exposure-response relationship. We noted that doubling of exposure could more than double the likelihood of a response without a statistically signifi cant increase in reported adverse events such as stomatitis. This fi nding suggests that increased exposure of everolimus might be a reasonable option for patients who do not demonstrate a satisfactory reduction in seizure frequency.
Existing antiepileptic drugs are thought to reduce seizure frequency through a direct antiseizure eff ect on neuronal hyperexcitability via γ-aminobutyric acid (GABA)-ergic or glutamatergic mechanisms. Clinical eff ects of antiepileptic drugs are observed rapidly (seizure reduction is noted within days of initiating treatment) and remains stable through the duration of treatment. 32, 33 The mechanism of action of everolimus and its clinical eff ects are more complex. Findings from animal models suggest that mTOR inhibitors, such as everolimus, have antiepileptogenic eff ects by altering signalling pathways and protein expression, and modifying downstream mechanisms involved in epileptogenesis. These mechanisms drive complex morphological changes to neuronal and glial cells that evolve over long periods of time in animal models. 12 Consistent with these observations, Krueger and colleagues 15 reported in a single-group study that everolimus reduced seizure frequency more in the later weeks than in earlier weeks of the 12-week study. This observation of a correlation between longer exposure and effi cacy has been confi rmed in this study, in which a clinically meaningful and statistically signifi cant reduction in seizure frequency continued to improve throughout the core phase. Pharmacokinetic modelling demonstrated that every 15 days of treatment delivered an additional 4·8% reduction in seizure frequency. This observation contrasts with that expected for levetiracetam 33 and other antiepileptic drugs, which typically do not exhibit time-dependent amelioration of clinical benefi t.
In conclusion, our fi ndings demonstrate that everolimus treatment of mixed-type seizures in patients with tuberous sclerosis complex, despite the high baseline burden of seizures in these individuals, can lead to a clinically meaningful reduction in seizure frequency with a favourable benefi t-risk ratio that improves with ongoing treatment. Everolimus, a disease-modifying drug targeting the underlying molecular pathology of tuberous sclerosis complex, represents a new treatment option for patients with treatment-resistant seizures associated with tuberous sclerosis complex. Further evaluation of mTOR inhibitors in patients with other diseases of treatmentresistant seizures and cortical malformations, resulting from PI3K-mTOR pathway mutations causing mTOR overactivation, could be warranted.
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